Managers

Companies look to security tokens to avoid regulatory surprises

Number of biotech deals drops as equity balloons

SyncThink appoints Yecies as CEO

Palo Alto, California-based SyncThink, a developer of eye-tracking technology products, has named Laura Yecies as CEO. SyncThink's backers include Quadrant Management Inc.

Harrison Metal raises $68 mln fifth fund

Harrison Metal has raised a $68 million fifth venture-capital fund, according to a filing with the SEC.

Cofounders Capital rakes in $20.5 mln for sophomore fund

Cofounders Capital has raised $20.5 million for its second fund, according to an SEC filing. The target is $50 million. The Cary, North Carolina-based firm is focused on software ventures in the Triangle.

Poseida Therapeutics snags $30.5 mln Series B

San Diego-based Poseida Therapeutics Inc, which translates gene engineering technologies into cell therapies, has raised $30.5 million in Series B financing. Longitude Capital led the round with participation from other investors that included Vivo Capital, the Tavistock Group and Malin Corporation plc. In conjunction with the financing, Dr. David Hirsch, a managing director at Longitude Capital, has joined Poseida’s board of directors.

Firebrand Ventures collects $17.7 mln for Midwest fund

Firebrand Ventures has closed its new fund at $17.7 million, beating its $7 million target, according to an announcement on its site. The Kansas City, Missouri-based venture firm invests in startups in the Greater Midwest.

Virta Health fetches $45 mln Series B

San Francisco-based Virta Health, an online specialty clinic that treats type 2 diabetes, has raised $45 million in Series B funding. The investors included Venrock, Obvious Ventures, Creandum, Caffeinated Capital, SciFi VC, Founders Fund and Playground Global.

VC-backed Inbox Health taps Gamble as COO

New Haven, Connecticut-based Inbox Health Inc, a patient billing and payments startup, has named Charles Gamble as chief operating officer. Gamble is the founder of Tangoe. Inbox Health's backers include Connecticut Innovations, Launch Capital, Enhanced Capital, I2BF Global Ventures and Mohawk Ventures.

Nextech Invest leads Series C round for Arvinas

New Haven, Connecticut-based Arvinas LLC, a developer of drugs based on protein degradation, has raised $55 million in Series C financing. Nextech Invest led the round with participation from other investors that included Deerfield Management, Hillhouse Capital, Sirona Capital, Canaan Partners, 5AM Ventures, RA Capital Management, OrbiMed and New Leaf Venture Partners. In addition to the funding, Dr. Jakob Loven, a partner at Nextech Invest, will join the Arvinas board of directors.